The patch is the first drug to be assessed for a controversial condition called hypoactive sexual desire disorder. Proctor & Gamble claims that the patch can increase sexual activity by 74%, which has generated enthusiastic media coverage. It has also urged an international medical society, which it sponsors, to endorse the patch at the FDA regulatory hearing.
But the marketing has caused concern among some sex researchers by failing to state that in absolute terms, the patch may only increase sexual activity by one "episode," or less, per month.
Although an increase of one sexual episode a month may be of value clinically to some women, this is overshadowed by serious doubts about the long term safety of testosterone, say experts.
Rosemary Basson, one of the leading authorities in the field of women's sexual difficulties, says much caution is needed in prescribing testosterone to women. Meanwhile, others have raised serious questions about the disorder because women's sexual "symptoms" may often be healthy adaptive responses and should not be regarded as evidence of dysfunction.
A second article charges media outlets with exaggerating the benefits of the patch in their search for sexy stories.
None of the key clinical trials of Proctor & Gamble's testosterone patch have been published in peer reviewed journals, yet for a year or more excited media reports have sung the praises of the latest panacea for women's "low sex drive," writes author, Ray Moynihan, who recently won an award from the British Medical Journalists' Association, for his BMJ articles on entanglement between doctors and drug companies.
"Give
'"/>
Contact: Emma Dickinson
edickinson@bmj.com
44-207-383-6529
BMJ-British Medical Journal
25-Nov-2004